Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.

Nishat S, Khan LA, Ansari ZM, Basir SF.

Curr Cardiol Rev. 2016;12(1):18-26. Review.

2.

Basal adenosine modulates the functional properties of AMPA receptors in mouse hippocampal neurons through the activation of A1R A2AR and A3R.

Di Angelantonio S, Bertollini C, Piccinin S, Rosito M, Trettel F, Pagani F, Limatola C, Ragozzino D.

Front Cell Neurosci. 2015 Oct 12;9:409. doi: 10.3389/fncel.2015.00409. eCollection 2015.

3.

Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation.

Jeon JS, Bersini S, Gilardi M, Dubini G, Charest JL, Moretti M, Kamm RD.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):214-9. doi: 10.1073/pnas.1417115112. Epub 2014 Dec 18. Erratum in: Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E818.

4.

Synthesis and evaluation of N⁶-substituted apioadenosines as potential adenosine A₃ receptor modulators.

Toti KS, Moss SM, Paoletta S, Gao ZG, Jacobson KA, Van Calenbergh S.

Bioorg Med Chem. 2014 Aug 1;22(15):4257-68. doi: 10.1016/j.bmc.2014.05.036. Epub 2014 May 23.

5.

Investigational A₃ adenosine receptor targeting agents.

Koscsó B, Csóka B, Pacher P, Haskó G.

Expert Opin Investig Drugs. 2011 Jun;20(6):757-68. doi: 10.1517/13543784.2011.573785. Epub 2011 Apr 2. Review.

6.

Recent developments in adenosine receptor ligands and their potential as novel drugs.

Müller CE, Jacobson KA.

Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23. Review.

7.

Xanthines as adenosine receptor antagonists.

Müller CE, Jacobson KA.

Handb Exp Pharmacol. 2011;(200):151-99. doi: 10.1007/978-3-642-13443-2_6. Review.

8.

Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG Jr, Jacobson KA.

Biochem Pharmacol. 2010 Apr 1;79(7):967-73. doi: 10.1016/j.bcp.2009.11.009. Epub 2009 Nov 14.

9.

Adenosine receptors and cancer.

Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA.

Handb Exp Pharmacol. 2009;(193):399-441. doi: 10.1007/978-3-540-89615-9_14. Review.

10.

Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG.

Handb Exp Pharmacol. 2009;(193):123-59. doi: 10.1007/978-3-540-89615-9_5. Review.

11.

Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor.

Gao ZG, Teng B, Wu H, Joshi BV, Griffiths GL, Jacobson KA.

Purinergic Signal. 2009 Mar;5(1):31-7. doi: 10.1007/s11302-008-9107-1. Epub 2008 Jun 5.

12.

2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors.

Volpini R, Costanzi S, Lambertucci C, Vittori S, Martini C, Trincavelli ML, Klotz KN, Cristalli G.

Purinergic Signal. 2005 Jun;1(2):173-81. doi: 10.1007/s11302-005-6216-y. Epub 2005 Mar 17.

13.

Invited Lectures : Overviews Purinergic signalling: past, present and future.

[No authors listed]

Purinergic Signal. 2006 May;2(1):1-324. doi: 10.1007/s11302-006-9006-2. Epub 2006 May 15. No abstract available.

14.

Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A₃ adenosine receptor ligands.

Dal Ben D, Lambertucci C, Taffi S, Vittori S, Volpini R, Cristalli G, Klotz KN.

Purinergic Signal. 2006 Nov;2(4):589-94. doi: 10.1007/s11302-006-9010-6. Epub 2006 Aug 10.

15.

Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes.

Bolcato C, Cusan C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Morizzo E, Moro S.

Purinergic Signal. 2008 Mar;4(1):39-46. doi: 10.1007/s11302-007-9058-y. Epub 2007 Jul 25.

16.

Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration.

Pugliese AM, Coppi E, Volpini R, Cristalli G, Corradetti R, Jeong LS, Jacobson KA, Pedata F.

Biochem Pharmacol. 2007 Sep 1;74(5):768-79. Epub 2007 Jun 7.

17.

2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.

Cosyn L, Palaniappan KK, Kim SK, Duong HT, Gao ZG, Jacobson KA, Van Calenbergh S.

J Med Chem. 2006 Dec 14;49(25):7373-83.

18.
19.

Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Van Rompaey P, Jacobson KA, Gross AS, Gao ZG, Van Calenbergh S.

Bioorg Med Chem. 2005 Feb 15;13(4):973-83.

Supplemental Content

Support Center